



# Prevalence of Multi-drug Resistant (mdr) *Pseudomonas sp.* Among Patients Attending in Tertiary Care Hospital, Dhaka City, Bangladesh

S. M. Kamrul Islam<sup>1,2</sup>, Maruf Abony<sup>2</sup>, Aneeka Nawar Fatema<sup>2</sup>, Suvamoy Datta<sup>2\*</sup>

## Abstract

The resistance pattern of *Pseudomonas sp.* isolates in recent years is increasing very rapidly because of the uncontrolled, unsupervised, and unnecessary usage of antibiotics. Current study aims to evaluate the prevalence of multidrug-resistant (MDR) *Pseudomonas sp.* isolated from clinical samples collected from tertiary care hospitals in Dhaka, Bangladesh. In this study, a total of 1440 samples were collected from January 2019 to September 2019, followed by using conventional methods, as well as the Kirby-Bauer disc diffusion method for culture and susceptibility of Samples, respectively. Finally, Stata 14 software was utilized to analyze the obtained data. From among 1440 samples, 480 (33.3%) cases were bacteriologically positive. Imipenem (11%) showed the least resistance followed by Meropenem (20%), where Nalidixic acid exhibited the highest drug resistance. Additionally, 202 (48.08%) and 278 (57.92%) cases were identified as MDR and non-drug-resistance (NDR). The number of male MDR cases was higher than females. It is alarming to increase MDR pathogens. This bacterial resistance can be prevented through control measures that limit the spread of resistant bacteria and the regular

monitoring of this resistance phenotype of pathogens, along with the rational use of antimicrobial therapy.

**Keywords:** Multidrug-resistant (MDR), *Pseudomonas sp.*, Kirby-Bauer disc diffusion, Tertiary care hospital, and Dhaka city.

## Introduction

*Pseudomonas sp.* is a leading cause of nosocomial infections. In developed countries of Western Europe annually four hundred thousand cases of hospital-acquired infections are reported among which a third are *Pseudomonas sp.* (Adeleye & Adetosoye, 1993; Aguilera-Sáez et al., 2019). Infections caused by *Pseudomonas sp.* are often severe and life-threatening and are difficult to treat because of the limited susceptibility to antimicrobial agents and the high frequency of emergence of antibiotic resistance during therapy (Algammal et al., 2020; Anthony et al., 2002; Asma et al., 2019) thus resulting in severe adverse outcomes (Baban, 2020; Berrouane et al., 2000; Bhuiya et al., 2018).

*Pseudomonas sp.* is a clinically important gram-negative bacterium, which is responsible for a variety of systemic infections like urinary tract infections, respiratory system infections, gastrointestinal infections, dermatitis, bacteremia, soft tissue infections, bone and joint infections (Bronzwaer et al., 2002). Due to its nominal nutritional requirement, *Pseudomonas sp.* can survive in soil, plant surfaces, wastewater, moist environment, surface water, or even on inert materials (Brun-Buisson et al., 1987). Using life support equipment, cosmetics, dilute antiseptics even through the washing liquids and soaps, it can be transmitted from person to person (Carmeli et al., 1999; Chaoui et al., 2019). However, *Pseudomonas*

**Significance** | Unchecked antibiotic use is making *Pseudomonas sp.* more resistant. To combat this, it's crucial to manage antibiotics responsibly.

\*Correspondence. Suvamoy Datta, Department of Microbiology, Primeasia University, Banani, Dhaka-1213, Bangladesh.  
E-mail: suvamoy.datta@primeasia.edu.bd

Editor Md Asaduzzaman Shishir, And accepted by the Editorial Board Dec 01, 2020 (received for review Sep 29, 2020)

## Author Affiliation.

<sup>1</sup> Department of Microbiology, Jashore University of Science and Technology, Jashore-7408, Bangladesh

<sup>2</sup> Department of Microbiology, Primeasia University, Banani, Dhaka-1213, Bangladesh

## Please cite this article.

S. M. Kamrul Islam, Maruf Abony et al. (2020). Prevalence of Multi-Drug Resistant (MDR) *Pseudomonas sp.* among patients attending in tertiary care hospital, Dhaka city, Bangladesh, *Journal of Primesia*, 1(1), 1-5, 560011

sp. is mostly acquired from the environment and spread person-to-person rarely (Clinical and Laboratory Standards Institute [CLSI], 2013). The problem of antibiotic resistance in *Pseudomonas* sp. is on the increase (Aguilera-Sáez et al., 2019). The high frequency of drug resistance results from newly emerging resistance in specific organisms after exposure to antibiotics (Algammal et al., 2020) and patient-to-patient spread of resistant organisms (Berrouane et al., 2000). Resistance after exposure to antibiotics may result in multidrug-resistant (MDR) *Pseudomonas* sp. *Pseudomonas* sp is highly ubiquitous in water systems and capable to acquire antibiotic resistance due to its low outer membrane permeability and extensive efflux pump system (Devi et al., 2020; Dimopoulos et al., 2020). The overall prevalence of antibiotic-resistant *Pseudomonas* sp is increasing, with up to 10% of global isolates found to be multidrug resistance (Gales et al., 2001). It is recognized as the second leading cause of gram-negative nosocomial infection and a major treatment challenge for *Pseudomonas* sp (Hauser et al., 2002; Jameson et al., 2018).

There are a huge number of hospitals and clinics in Dhaka City due to being a densely populated city, where antibiotics are used frequently. The use of antibiotics is included but is not limited to medicine, veterinary medicine, and growth promoters in animal husbandry, fish farming, etc. After use antibiotics are often released into the water. Frequent use of antibiotics in treatments plays an important role in the emergence of resistant bacteria (Kato et al., 2001; Khan et al., 2020). Antibiotic producing pharmaceuticals are located in areas that are close to water reservoirs and very few of them maintain the guidelines to dispose of effluents in ponds, rivers, and other water systems.

The presence of antibiotic-resistant microbes has been observed in wastewater, surface water, groundwater, sediments, and soils. With changing and increasing resistance observed in clinically significant bacteria, it is important to detect drug-resistant microorganisms. In the past two decades, the emergence of resistance to antimicrobial agents has been repented as one of the most important clinical crises (Kugelberg et al., 2005; Kutty, 2011). Because of variety among beta-lactamases, alterations in binding proteins and outer membrane permeability, and multiple mechanisms of resistance, the gram-negative bacteria have acquired resistance against extended-spectrum Cephalosporins, Monobactams, and Carbapenems and (Lai et al., 2018). Extended spectrum beta-lactamases (ESBLs) are an important reason for bacterial resistance throughout the world (Law et al., 2019). As ESBL producing isolates can hydrolyze 3rd and 4th generation Cephalosporins and Mono-bactams Microbiologists, clinicians, infection control professionals, and scientists are hard-pressed to find new antimicrobial agents. ESBL producing strains are only inhibited by beta-lactamase inhibitors,

clavulanic acid, sulbactam, and tazobactam (Liao et al., 2019; Lister et al., 2009; Moradali et al., 2017).

## Materials and Methods

### *Isolation of Pseudomonas spp.*

Blood Samples were collected and transported to the Department of Microbiology, Primeasia University at the earliest convenience, and samples were inoculated directly onto MacConkey's, blood, and Cetrimide agar plates in triplicate. Cetrimide agar was used for selective isolation of *Pseudomonas* sp.. The plates were then incubated overnight at 37°C in an incubator (Binder, Germany) and examined for non-lactose fermenting pale colonies (Nathwani et al, 2014).

### *Identification of Pseudomonas spp.*

#### Morphological characteristics & microscopy

Gram-negative rods were expected in gram staining. The organism on the MacConkey agar plate produced non-lactose fermenting transparent greenish colonies (Nathwani et al, 2014) Green color colonies were observed on cetrimide agar.

### *Biochemical test*

The isolated *Pseudomonas* spp. were further confirmed by biochemical tests following the procedure by using biochemical tests like Triple Sugar Iron (TSI-Oxoid), Motility Indole Urea (MIU-Oxoid), and Simmons Citrate (Oxoid) agar [29]. Kovac's reagent (LOBA Chem, Italy) was used to detect tryptophan hydrolysis for the Indole test. In comparison to other modern and rapid tests, biochemical tests were selected as a method of identifying isolates due to their availability and cost-effectiveness for the current study.

### *Determination of antimicrobial susceptibility*

Bacterial susceptibility to antimicrobial agents was determined by using the Kirby-Bauer disc-diffusion method and Clinical and Laboratory Standard Institute guidelines (CLSI), by using antibiotic-containing disks from Oxoid Ltd, UK as well as the manufacturer instructions about the clear zones of growth inhibition around the disks (Paghdar et al, 2020; Palavutitotai et al, 2018)

### *Statistical analysis*

The chi-square test was utilized to compare the groups and  $P < 0.05$  was considered as statistically significant which was determined using Microsoft excel 2007 (NNIS, 1992).

## Results and Discussion

### *Isolation and identification of Pseudomonas spp.*

Out of 1440 samples, 480 positive samples (30%) were isolated and later identified as *Pseudomonas* sp. based on their morphological characteristics and biochemical characteristics (Ray et al, 2010).

### *Determination of antimicrobial susceptibility*

Results from antimicrobial activity revealed that Imipenem is the best drug for treatment against *Pseudomonas* sp. based on the current study, followed by Meropenem. However, other generation cephalosporin drugs showed higher resistance in comparison to Ceftazidime. Cotrimoxazole also exhibited satisfactory results based on antibiograms (Ray et al, 2010).

#### **Statistical analysis**

Statistical analysis was conducted as ANOVA, which revealed a significant value with P-value < 0.05 (0.008) (Roy-Burman et al, 2001).

To study the prevalence of multidrug-resistant of *Pseudomonas* sp, a total of 1440 *Pseudomonas* sp infection suspected population was diagnosed but 480 samples were found *Pseudomonas* sp. positive. Fattma et. al. showed a 13.88% positive culture among 144 total samples (Nathwani et al, 2014). A recent study found 30% positive for a urine sample, the most common source of isolation. However, our study has not categorized the different samples but has found a similar finding, of a 30% positive prevalence of *Pseudomonas* sp. (Ray et al, 2010).

The emergence of MDR *Pseudomonas* sp (resistant to Cephalexin, Cepheparadine, and co-trimoxazole) initiated, consistent use of fluoroquinolones that had proven to be effective for the treatment of *Pseudomonas* infection. This study has been conducted to observe the prevalence and antibiotic susceptibility pattern of *Pseudomonas* sp in Dhaka city (Ray et al, 2010).

It was seen that 11% (Imipenem) to 57% (Nalidixic Acid) of the *Pseudomonas* sp. strains are resistant to the antibiotics used against them. Imipenem (89 % sensitive) is the best drug for the treatment of *Pseudomonas* sp. infection followed by Meropenem (70% sensitive) where 10% of meropenem isolates were moderately sensitive. The results of Fattma et.al showed that the most effective antibiotics were Pip/Tazo and Imipenem (80% sensitivity), followed by Meropenem and Amikacin (75% sensitivity) (Nathwani et al, 2014).. That result is similar to findings to the current study in the case of Imipenem and Meropenem. Shi et. al showed that 41.8 and 25.6% of patients were admitted to the ICU due to *Pseudomonas* auroginosa infection as well as exhibiting hospitalized patients having a record of prior exposure to antibiotics or immunological system defects, which leads to resistance against antibiotics. Therefore, this may contribute to the reason of other drugs being resistant, in the current study compared to that of a previous study (Seppänen et al, 2008). In a total of 480 samples, 61 cases (76.25%) and 38 cases (47.50%) were reported positive for multidrug-resistant in females above and below 30 years of age respectively.

In the case of Multidrug resistance sixty-one out of eighty samples (76.25%) were multidrug-resistant found in the sample of elder females, thirty-eight among eighty samples (47.50%) were multidrug-resistant found in the sample of young females, forty-

four out of eighty samples (55%) were multidrug-resistant found in the sample of young male & fifty-nine samples (73.75%) were multidrug-resistant found in the sample of elder males. Furthermore, 202 of the samples (42.08%) were resistant to at least 5 antibiotics. In a conducted study it was found that 56 (22%) strains were XDR-PA, 32 (12.5%) were MDR-PA, 167 (65.5%) were non-MDR PA, and 0 were PDR-PA strains out of a total of 255 patients (Shi et al, 2019; Tang et al, 2018). A meta-analysis conducted had reported that all isolates in two studies were completely MDR (100%). While in another study it showed, 44.4% and 18.2% MDR and XDR respectively among *Pseudomonas* auroginosa isolates (Uddin et al, 2018) which has a higher relevance in findings compared to that of other findings which exhibited lower drug-resistant pattern among isolates (Uddin et al, 2018; Vandewoude et al, 2000).

#### **Conclusion**

In developing countries, the prevalence of *Pseudomonas* sp. is alarmingly high whereas, in developed countries the incidence of *Pseudomonas* sp. is rare comparatively. Furthermore, the findings conclude that the main concern of the high infection is the multi-drug resistant phenomenon which is identified in commonly used antibiotics. However, current studies use the antibiotic, Imipenem as a preferred drug for testing sensitivity but in this study isolates of *Pseudomonas* sp. have displayed a significant 11% resistance. In patients with an immunocompromised system, the infection will transmit faster resulting in diseases like pneumonia, endocarditis, peritonitis, meningitis, ecthyma gangrenosum (EG), bacteremia, and septicemia.

#### **Author contributions**

S.D., conceptualized and developed the methodology, S.M.K.I., and M.A., prepared the original draft and collected, A.N.F., reviewed and edited the writing.

#### **Acknowledgment**

The author thanks the Department of Microbiology, Primeasia University, Banani, Dhaka-1213, Bangladesh

#### **Competing financial interests**

The authors have no conflict of interest.

#### **References**

- Adeleye I, Adetosoye A 1993: Antimicrobial resistance patterns and plasmid survey of *Salmonella* and *Shigella* isolated in Ibadan, Nigeria. *East African medical journal* 70(5): 259-262.

- Aguilera-Sáez J, Andreu-Solà V, Escartín NL, Garrido VR, Gil LA, García JS 2019: Extensively drug-resistant *Pseudomonas aeruginosa* outbreak in a burn unit: Management and solutions. *Annals of Burns and Fire Disasters* 32(1): 47.
- Algammal AM, Mabrok M, Sivaramasamy E, Youssef FM, Atwa MH, El-Kholy AW, et al. 2020: Emerging MDR-*Pseudomonas aeruginosa* in fish commonly harbor oprL and toxA virulence genes and blaTEM, blaCTX-M, and tetA antibiotic-resistance genes. *Scientific Reports* 10(1): 1-12.
- Anthony M, Rose B, Pegler MB, Elkins M, Service H, Thamotharampillai K, 2002: Genetic analysis of *Pseudomonas aeruginosa* isolates from the sputa of Australian adult cystic fibrosis patients. *Journal of Clinical Microbiology* 40(8): 2772-2778.
- Asma R, Alam MJ, Rahimgir M, Asaduzzaman M, Islam AM, Uddin N, Khan MSI, Jahan N, Siddika SS, Datta S 2019: Prevalence of Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Uropathogens Isolated From Urinary Tract Infection Cases in Dhaka, Bangladesh. *Avicenna Journal of Clinical Microbiology and Infection* 6(2): 44-48.
- Baban ST 2020: Molecular detection of carbapenemase-producing *Pseudomonas aeruginosa* isolated from intensive care units of surgical specialty hospital in Erbil city. *Medical Journal of Babylon* 17(2): 185.
- Berrouane YF, McNutt L-A, Buschelmann BJ, Rhomberg PR, Sanford MD, Hollis RJ, 2000: Outbreak of severe *Pseudomonas aeruginosa* infections caused by a contaminated drain in a whirlpool bathtub. *Clinical infectious diseases* 31(6): 1331-1337.
- Bhuiya M, Sarkar MK, Sohag MH, Ali H, Roy CK, Akther L. 2018: Enumerating antibiotic susceptibility patterns of *Pseudomonas aeruginosa* isolated from different sources in Dhaka City. *The open microbiology journal* 12: 172.
- Bronzwaer SL, Cars O, Buchholz U, Mölstad S, Goettsch W, Veldhuijzen IK. 2002: The relationship between antimicrobial use and antimicrobial resistance in Europe. *Emerging infectious diseases* 8(3): 278.
- Brun-Buisson C, Philippon A, Ansquer M, Legrand P, Montravers F, Duval J 1987: Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant *Klebsiella pneumoniae*. *The Lancet* 330(8554): 302-306.
- Carmeli Y, Troillet N, Karchmer AW, Samore MH 1999: Health and economic outcomes of antibiotic resistance in *Pseudomonas aeruginosa*. *Archives of Internal Medicine* 159(10): 1127-1132.
- Chaoui L, Mhand R, Mellouki F, Rhallabi N 2019: Contamination of the surfaces of a health care environment by multidrug-resistant (MDR) bacteria. *International journal of microbiology* 2019.
- Clinical and Laboratory Standards Institute (CLSI) 2013: Performance standard for antimicrobial susceptibility testing. 23rd International Supplement Document 33 : 1-199.
- Devi LS, Broor S, Rautela RS, Grover SS, Chakravarti A, Chattopadhyaya D 2020: Increasing prevalence of *Escherichia coli* and *Klebsiella pneumoniae* producing CTX-M-type extended-spectrum beta-lactamase, carbapenemase, and NDM-1 in patients from a rural community with community acquired infections: A 3-year study. *International Journal of Applied and Basic Medical Research* 10(3): 156.
- Dimopoulos G, Akova M, Rello J, Poulakou G 2020: Understanding resistance in *Pseudomonas*. *Intensive care medicine* 46(2): 350-352.
- Gales A, Jones R, Turnidge J, Rennie R, Ramphal R 2001: Characterization of *Pseudomonas aeruginosa* isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. *Clinical infectious diseases* 32(2): 146-155.
- Hauser AR, Cobb E, Bodí M, Mariscal D, Vallés J, Engel JN, et al. 2002: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by *Pseudomonas aeruginosa*. *Critical care medicine* 30(3): 521-528.
- Jameson JL, Kasper DL, Fauci AS, Hauser SL, Longo DL, Loscalzo J 2018: Harrison's principles of internal medicine. McGraw-hill education. New York
- Kato K, Iwai S, Kumasaka K, Horikoshi A, Inada S, Inamatsu T 2001: Survey of antibiotic resistance in *Pseudomonas aeruginosa* by the Tokyo Johoku Association of *Pseudomonas* Studies. *Journal of infection and chemotherapy* 7(4): 258-262.
- Khan H, Bari F, Masood A, Ghani F, Khan Z, Khan WY 2020: Phenotypic Detection of Extended Spectrum Beta-Lactamases in Uro-pathogens. An Experience from Qazi Hussain Ahmed Medical Complex, Nowshera. *Journal of Rawalpindi Medical College* 24(1): 40-45.
- Kugelberg E, Löfmark S, Wretling B, Andersson DI 2005: Reduction of the fitness burden of quinolone resistance in *Pseudomonas aeruginosa*. *Journal of Antimicrobial Chemotherapy* 55(1): 22-30.
- Kutty N 2011: Treating children without antibiotics in primary healthcare. *Oman Medical Journal* 100(325): 1-3
- Lai C-C, Chen C-C, Lu Y-C, Lin T-P, Chuang Y-C, Tang H-J 2018: Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms. *Infection and Drug Resistance* 11: 1441.
- Law N, Logan C, Yung G, Furr C-LL, Lehman SM, Morales S, et al. 2019: Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant *Pseudomonas aeruginosa* infection in a cystic fibrosis patient. *Infection* 47(4): 665-668.
- Liao S, Zhang Y, Pan X, Zhu F, Jiang C, Liu Q, et al. 2019: Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant *Pseudomonas aeruginosa*. *International journal of nanomedicine* 14: 1469.
- Lister PD, Wolter DJ, Hanson ND 2009: Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clinical microbiology reviews* 22(4): 582-610.
- Moradali MF, Ghods S, Rehm BH 2017: *Pseudomonas aeruginosa* lifestyle: a paradigm for adaptation, survival, and persistence. *Frontiers in cellular and infection microbiology* 7: 39.
- Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V 2014: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant *Pseudomonas aeruginosa* infections: a systematic review and meta-analysis. *Antimicrobial resistance and infection control* 3(1): 1-16.
- National Nosocomial Infections Surveillance (NNIS) System Report 2004: National Nosocomial Infection Surveillance from January 1992 through June 2004. *American Journal of Infection Control* 32: 470-485.
- Paghdar D, Nayak J, Mathakiya R, Parmar B, Gida H, Bhavsar P 2020: Isolation and Molecular Characterization of Extended Spectrum Beta Lactamase Producing *Escherichia coli* from Milk. *Journal of Animal Research* 10(1): 143-148.

- Palavutitotai N, Jitmuang A, Tongchai S, Kiratisin P, Angkasekwinai N 2018: Epidemiology and risk factors of extensively drug-resistant *Pseudomonas aeruginosa* infections. *Plos one* 13(2): 1-13.
- Ray CG, Ryan KJ 2010: *Sherris medical microbiology*. 6th ed, McGraw-Hill. New York
- Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J. 2001: Type III protein secretion is associated with death in lower respiratory and systemic *Pseudomonas aeruginosa* infections. *The Journal of infectious diseases* 183(12): 1767-1774.
- Seppänen L, Lauhio A, Lindqvist C, Suuronen R, Rautemaa R 2008: Analysis of systemic and local odontogenic infection complications requiring hospital care. *Journal of Infection* 57(2): 116-122.
- Shi Q, Huang C, Xiao T, Wu Z, Xiao Y 2019: A retrospective analysis of *Pseudomonas aeruginosa* bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and non-susceptible infections. *Antimicrobial Resistance & Infection Control* 8(1): 1-9.
- Tang SY, Zhang SW, Wu JD, Wu F, Zhang J, Dong JT 2018: Comparison of mono- and combination antibiotic therapy for the treatment of *Pseudomonas aeruginosa* bacteraemia: A cumulative meta-analysis of cohort studies. *Experimental and therapeutic medicine* 15(3): 2418-2428.
- Tkhilashvili T, Winkler T, Müller M, Perka C, Trampuz A 2019: Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy* 64(1): e00924-00919.
- Uddin ME, Akter T, Sultana P, Hasan MI, Lubna MA, Al Monem H 2018: Isolation, identification and antimicrobial susceptibility profile analysis of *Vibrio cholerae* O1 from stool samples of Bangladesh. *Advances in Microbiology* 8(3): 188-196.
- Vandewoude KH, Blot SI, Hoste EA 2000: Antibiotic resistance and exposure to different generation cephalosporins. *Critical care medicine* 28(7): 2678
- Weinstein RA, Gaynes R, Edwards JR, System NNIS 2005: Overview of nosocomial infections caused by gram-negative bacilli. *Clinical infectious diseases* 41(6): 848-854.